(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301
NCT06073821
 Interruption temporaire
|
CHU DE QUEBEC – UNIVERSITE LAVAL
 HOPITAL DE L'ENFANT-JESUS
|
|
Philippe Nadeau
418-649-0252 poste 63115
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301
NCT06073821
Interruption temporaire
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Chantal Gosselin
514-890-8000 poste 24892
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301
NCT06073821
Interruption temporaire
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Fanny Raquepas Trudel
450-466-5000 poste 3593
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301
NCT06073821
Interruption temporaire
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
(EN) A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
MK-1026-003
NCT04728893
 Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
|
Nawel Mechtouf
514-252-3400 poste 4681
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301
NCT06073821
Interruption temporaire
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Anick Champoux
819-346-1110 poste 12811
|
(EN) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy
MK-1026-010 (BELLWAVE-010)
NCT05947851
Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Christine Lawson
819-346-1110 poste 12942
|
(EN) A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MK-1026-011 (BELLWAVE-011)
NCT06136559
Actif en recrutement
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
|
Marie-Eve Fournier
418-724-3000 poste 8029
|
(EN) A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRUIN CLL-322
NCT04965493
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Edrian Gabrielle Bumanlag
514-840-8222 poste 23638
|
(EN) A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
MK-2140-006
NCT05458297
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Edrian Gabrielle Bumanlag
514-840-8222 poste 23638
|
Groupe d'étude en oncologie du Québec